Scotiabank Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)

In a report released today, George Farmer from Scotiabank maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $85.00. The company’s shares closed yesterday at $91.20.

Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Syndax Pharmaceuticals, and Biogen. According to TipRanks, Farmer has an average return of 15.8% and a 52.63% success rate on recommended stocks.

In addition to Scotiabank, BioMarin Pharmaceutical also received a Hold from RBC Capital’s Luca Issi in a report issued yesterday. However, on the same day, Jefferies assigned a Buy rating to BioMarin Pharmaceutical (NASDAQ: BMRN).

BMRN market cap is currently $17.47B and has a P/E ratio of 105.67.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMRN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioMarin Pharmaceutical (BMRN) Company Description:

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.